You may remember that not so long ago I wrote about what looked like a drug discovery success story for pain: anti-NGF therapy for osteoarthritis. Well, it looks like that success was short-lived. Somehow I missed this over the Christmas break, but, the FDA has ended trials on anti-NGF therapies for osteoarthritis due to development of avascular necrosis in some patients. Nothing positive can come of avascular necrosis and the pulling of several trials would suggest that this is a drug class effect (or at least suspected to be). Anyway you cut it, this is bad news.
- Amazing work from the Dalva lab!! lnkd.in/eDWVvpQ 4 years ago
- Short blog post on our work on AMPK activators for chronic pain: bodyinmind.org/ampk-metformin… 9 years ago
- NIH spends less than $0.50 per migraine patient on migraine research americanmigrainefoundation.org/support-the-fo… 9 years ago
- New article by yours truly on Pain Research Forum... What's up with PKMzeta? painresearchforum.org/news/23452-wha… 10 years ago
- or this one: informahealthcare.com/doi/abs/10.310… Thanks a ton 10 years ago
- anyone have access to this? onlinelibrary.wiley.com/doi/10.1016/j.… PDF to juniorprofblog at gmail dot com 10 years ago
Being sensitive (or… on What is hyperalgesia? What is… Abdul Qadir on Here is some data for Southern… Cassondra Cuello on Rescued from deep inside a thr… AzartplayCasinoJoumn on Rescued from deep inside a thr… Vardin73 on Postdoc to PI transition: How…
Grab the feed
- A Blog Around The Clock
- Bike Monkey
- Blue Lab Coats
- Body in Mind
- Daily Transcript
- Dr. Jekyll & Mrs. Hyde
- Drugmonkey apparently everywhere
- Drugmonkey WP
- Economists View
- Gene Expression
- In the pipeline
- Junction Potential
- Juniper Shoemaker
- Medical Writing, Editing and Grantsmanship
- Pal MD
- Professor Chaos
- Take as Directed
- Terra Sigillata
- The Intersection
- The Sartorialist
- The Thoughtful Animal
- Thus Spake Zuska
- Trapped in the USA
- Yackety Yak
- 535,704 fans
Ugh, that is such a bummer, for the process and especially for the patients in the trials who were hopeful and now have even more problems. It also shows just how complex this signaling is, and how hard it is to predict the full picture of the combinatorial biological effects of modulating it.
Ugh, that is such a bummer, not just for the field but also for the patients who were probably so hopeful. I guess it ends up being a good real-world example of just how complex this signaling biology is, and how combinatorially important NGF interactions must be in different physiological mechanisms. In cancer, you can get away with a lot more because the alternatives are so crappy, but all of these signaling disruptors come at a cost that hasn’t been adequately addressed in the signaling therapeutics “magic bullet” world.
Hey, I added your link: https://juniorprof.wordpress.com/2011/02/01/so-much-for-that to my article under the title So much for that | JUNIORPROF.
Hey, I added your link: https://juniorprof.wordpress.com/2011/02/01/so-much-for-that to my blog under the title So much for that | JUNIORPROF.